For US Healthcare Professionals

For US Healthcare Professionals

Image of 2 snakes. The left snake is easy to see, while the right snake is camouflaged and harder to see.

SPOT THE HIDDEN PREDATOR

Focus on the threat that’s lurking in nAMD and DME: Ang-2, and its ability to inhibit the Ang-Tie pathway1,2

Although current nAMD and DME therapies have successfully focused on inhibiting the VEGF pathway, there’s more to uncover about the crucial role angiopoietins play in vascular instability.1,3-6 What else is there to learn about VEGF and Ang-2?

Cconnecting with the retinal community


The landscape of retinal science is changing, especially how we approach multifactorial diseases. That’s why, at Genentech, we are not just pioneering new territory alone—we are pioneering it with you.

Every innovation begins with vision.

Ang-2=angiopoietin-2; Ang-Tie=angiopoietin/Tie; DME=diabetic macular edema; nAMD=neovascular age-related macular degeneration; VEGF=vascular endothelial growth factor.

    • Saharinen P, et al. Nat Rev Drug Discov. 2017;16:635-661. 

      Saharinen P, et al. Nat Rev Drug Discov. 2017;16:635-661. 

    • Fiedler U, et al. Nat Med. 2006;12:235-239. 

      Fiedler U, et al. Nat Med. 2006;12:235-239. 

    • MACUGEN [prescribing information]. Bridgewater, NJ: Valeant Pharmaceuticals North America LLC; 2016. 

      MACUGEN [prescribing information]. Bridgewater, NJ: Valeant Pharmaceuticals North America LLC; 2016. 

    • LUCENTIS [prescribing information]. South San Francisco, CA: Genentech, Inc; 2018. 

      LUCENTIS [prescribing information]. South San Francisco, CA: Genentech, Inc; 2018. 

    • BEOVU [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2020. 

      BEOVU [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2020. 

    • EYLEA [prescribing information]. Tarrytown, NY: Regeneron Pharmaceuticals, Inc; 2019.

      EYLEA [prescribing information]. Tarrytown, NY: Regeneron Pharmaceuticals, Inc; 2019.

    • Mulligan K, et al. JAMA Ophthalmol. 2020;138(1):40-47.

      Mulligan K, et al. JAMA Ophthalmol. 2020;138(1):40-47.

    • Baumal CR. Am J Manag Care. 2020;26(5 suppl):S103-S111.

      Baumal CR. Am J Manag Care. 2020;26(5 suppl):S103-S111.

    • Kim E, et al. Curr Diab Rep. 2019;19(68):1-10.

      Kim E, et al. Curr Diab Rep. 2019;19(68):1-10.

    • Romero-Aroca P. World J Diabetes. 2011;2(6):98-104.

      Romero-Aroca P. World J Diabetes. 2011;2(6):98-104.

    • Hakanpaa L, et al. Nat Commun. 2015;6:1-12.

      Hakanpaa L, et al. Nat Commun. 2015;6:1-12.

    • Augustin HG, et al. Nat Rev Mol Cell Biol. 2009;10:165-177.

      Augustin HG, et al. Nat Rev Mol Cell Biol. 2009;10:165-177.

    • Nambu H, et al. Gene Ther. 2004;11:865-873.

      Nambu H, et al. Gene Ther. 2004;11:865-873.

    • Mueller SB, et al. J Clin Invest. 2016;126(9):3188-3191.

      Mueller SB, et al. J Clin Invest. 2016;126(9):3188-3191.

    • Bolinger MT, et al. Int J Mol Sci. 2016;17:1-23.

      Bolinger MT, et al. Int J Mol Sci. 2016;17:1-23.

    • Bressler SB. Ophthalmology. 2009;116:S1-S7.

      Bressler SB. Ophthalmology. 2009;116:S1-S7.

    • Scott IU, et al. Diabetes and Ocular Disease: Past, Present, and Future Therapies. 2010. Oxford; New York: Oxford University Press in cooperation with the American Academy of Ophthalmology.

      Scott IU, et al. Diabetes and Ocular Disease: Past, Present, and Future Therapies. 2010. Oxford; New York: Oxford University Press in cooperation with the American Academy of Ophthalmology.

    • Clapp C, et al. Physiol Rev. 2009;89:1177-1215.

      Clapp C, et al. Physiol Rev. 2009;89:1177-1215.

    • Kienast Y, et al. Clin Cancer Res. 2013;19:6730-6740.

      Kienast Y, et al. Clin Cancer Res. 2013;19:6730-6740.

    • Klaassen I, et al. Prog Retin Eye Res. 2013;1-30.

      Klaassen I, et al. Prog Retin Eye Res. 2013;1-30.

    • Bhisitkul RB. Br J Ophthalmol. 2006;90:1542-1547.

      Bhisitkul RB. Br J Ophthalmol. 2006;90:1542-1547.

    • Shibuya M. Genes Cancer. 2011;2:1097-1105.

      Shibuya M. Genes Cancer. 2011;2:1097-1105.

    • Ciulla TA, et al. Ophthalmol Retina. 2020;4:19-30

      Ciulla TA, et al. Ophthalmol Retina. 2020;4:19-30

    • Hahn P, ed. ASRS 2020 Preferences and Trends Membership Survey. American Society of Retina Specialists; 2020.

      Hahn P, ed. ASRS 2020 Preferences and Trends Membership Survey. American Society of Retina Specialists; 2020.

    • Cohen SY, et al. Retina. 2013;33:474-481.

      Cohen SY, et al. Retina. 2013;33:474-481.

    • Holz FG, et al. Br J Ophthalmol. 2015;99:220-226.

      Holz FG, et al. Br J Ophthalmol. 2015;99:220-226.

    • Holekamp NM, et al. Am J Ophthalmol. 2018;191:83-91.

      Holekamp NM, et al. Am J Ophthalmol. 2018;191:83-91.